All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Current Health Ltd., of Edinburgh, Scotland, scooped up $11.5 million in a series A financing that was led by MMC Ventures. The funds are earmarked to scale up Current Health’s patient management platform, with the aim of preventing global illness in 1 million patients by 2021. Legal & General Group plc, a London-based financial services company, was the largest investor in the round and represents Current Health’s first corporate investor.
BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on biologic candidate SCB-313, developed with its Trimer-Tag technology platform.
The mechanical removal of clots from the brain has become increasingly standard in ischemic stroke cases. Last year, the American Heart Association/American Stroke Association guidelines expanded the recommended window for its use up to 24 hours an event. Aspiration-based device stroke treatment startup Imperative Care Inc. has now raised an $85 million series C round to back the marketing of two recently cleared products on this front.
TORONTO – Synaptive Medical Inc. has completed the first round of a new preferred equity investment totaling $25 million led by Guelph-Ontario-based Linamar Corp., which also entered into a manufacturing agreement with Synaptive, and Calgary’s Audible Capital Corp.
BEIJING – Chinese transcatheter heart valve developer Venus Medtech (Hangzhou) Inc. on Tuesday saw its share prices jump around 20% on its debut on the Hong Kong Stock Exchange (HKEX), an excellent start for a prerevenue med-tech IPO.
LONDON – Biotech billionaire Bob Duggan is taking a majority stake in Summit Therapeutics plc, as part of a proposed subscription and placing to raise $50 million. The scheme has to be voted through by shareholders, but assuming it is approved, Duggan will control approximately 73% of Summit’s enlarged share capital. Duggan previously invested $25 million in the company at the start of 2019, and already holds 49% of the stock.
DUBLIN – Immunos Therapeutics AG raised CHF15 million (US$15.2 million) in a series A round to move a novel immuno-oncology platform designed to turn cold tumors hot into early clinical development.
RSS
